Lipocine Management

Management criteria checks 3/4

Lipocine's CEO is Mahesh Patel, appointed in Jan 1997, has a tenure of 27.92 years. total yearly compensation is $860.34K, comprised of 61% salary and 39% bonuses, including company stock and options. directly owns 2.01% of the company’s shares, worth $523.13K. The average tenure of the management team and the board of directors is 7.1 years and 10.9 years respectively.

Key information

Mahesh Patel

Chief executive officer

US$860.3k

Total compensation

CEO salary percentage61.0%
CEO tenure27.9yrs
CEO ownership2.0%
Management average tenure7.1yrs
Board average tenure10.9yrs

Recent management updates

Recent updates

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Sep 26

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Feb 22
Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Sep 14
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression

Jun 14

Lipocine competitor prevails in patent infringement lawsuit for Jatenzo

May 26

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

May 11
When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

Lipocine EPS beats by $0.01

May 06

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Jan 26
Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Lipocine announces positive results from phase 2biopsy-confirmed NASH study

Jan 12

FDA Ok's Lipocine's testosterone replacement therapy, tentatively

Dec 09

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Dec 04
Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Lipocine EPS misses by $0.01

Nov 10

Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection

Nov 06

CEO Compensation Analysis

How has Mahesh Patel's remuneration changed compared to Lipocine's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$860kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$884kUS$494k

-US$11m

Sep 30 2022n/an/a

US$4m

Jun 30 2022n/an/a

US$3m

Mar 31 2022n/an/a

-US$754k

Dec 31 2021US$1mUS$471k

-US$634k

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$994kUS$457k

-US$21m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$521kUS$457k

-US$13m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$1mUS$439k

-US$12m

Sep 30 2018n/an/a

-US$14m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$1mUS$435k

-US$21m

Compensation vs Market: Mahesh's total compensation ($USD860.34K) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Mahesh's compensation has been consistent with company performance over the past year.


CEO

Mahesh Patel (67 yo)

27.9yrs

Tenure

US$860,343

Compensation

Dr. Mahesh V. Patel, Ph D., co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997 and serves as its Interim Principal Financial Officer since January 31, 2...


Leadership Team

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder27.9yrsUS$860.34k2.01%
$ 523.1k
Krista Fogarty
Principal Accounting Officer & Corporate Controller6.2yrsUS$321.07k0.014%
$ 3.6k
Nachiappan Chidambaram
Senior Vice President of Research & Development2yrsUS$385.71k0.074%
$ 19.2k
Logan Morse
Vice President of Sales7.7yrsUS$633.01kno data
Anthony DelConte
Chief Medical Director7.1yrsno datano data

7.1yrs

Average Tenure

56yo

Average Age

Experienced Management: LPCN's management team is seasoned and experienced (7.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder27.9yrsUS$860.34k2.01%
$ 523.1k
Richard Ono
Independent Director10.9yrsUS$75.03k0.016%
$ 4.0k
Leslie Benet
Member of Scientific Advisory Boardno datano datano data
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Jeffrey Fink
Independent Director10.9yrsUS$79.66k0.0072%
$ 1.9k
George Zografi
Member of Scientific Advisory Boardno datano datano data
Tsuneji Nagai
Member of Scientific Advisory Boardno datano datano data
Alan Hofmann
Member of Scientific Advisory Boardno datano datano data
Norman Ho
Member of Scientific Advisory Boardno datano datano data
Rex Hjelm
Member of Scientific Advisory Boardno datano datano data
John Higuchi
Director21.9yrsUS$62.28k0.76%
$ 198.7k
Spyridon Papapetropoulos
Lead Independent Director & Chairman of the Board2.7yrsUS$91.91k0.024%
$ 6.2k

10.9yrs

Average Tenure

66.5yo

Average Age

Experienced Board: LPCN's board of directors are seasoned and experienced ( 10.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:06
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lipocine Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
John NewmanCanaccord Genuity
Corey DavisCanaccord Genuity